Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Myriad GeneticsFRA:MYD +1.90%42 Equity-to-Asset is 0.48 as of Jun. 2026, which is 29% below its 10-year median of 0.68. GuruFocus rates FRA:MYD with a GF Score™ of 42/100 and a GF Value™ of €9.49 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 63.98% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Myriad Genetics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €263.8 Mil. Myriad Genetics's Total Assets for the quarter that ended in Jun. 2026 was €554.6 Mil.
Therefore, Myriad Genetics's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.48.
The historical rank and industry rank for Myriad Genetics's Equity-to-Asset or its related term are showing as below:
FRA:MYD'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48 Med: 0.68 Max: 0.82
Current: 0.48
During the past 13 years, the highest Equity to Asset Ratio of Myriad Genetics was 0.82. The lowest was 0.48. And the median was 0.68.
FRA:MYD's Equity-to-Asset is ranked worse than 63.98% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs FRA:MYD: 0.48
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Myriad Genetics Equity-to-Asset Related Terms
Myriad Genetics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MYD vs BDSX, XGN, IMDX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Myriad Genetics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (FRA:MYD) has a Equity-to-Asset of 0.48 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Myriad Genetics and its competitors. This is 29% below median its historical median of 0.68. Over the past decade, Myriad Genetics' Equity-to-Asset has ranged from 0.48 to 0.82. According to the industry distribution chart, Myriad Genetics ranks #135 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 64%.
Is Myriad Genetics' Equity-to-Asset too high?
Myriad Genetics' current Equity-to-Asset of 0.48 is 29% below median its 10-year median of 0.68. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 0.82. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Myriad Genetics' value of 0.48 is 18.6% below this industry median. Based on the distribution chart, Myriad Genetics ranks #135 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Myriad Genetics has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Equity-to-Asset compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #135 out of 211 companies for Equity-to-Asset. This places Myriad Genetics in the lower half of its industry. The industry median Equity-to-Asset is 0.59. Myriad Genetics' value of 0.48 is 18.6% below this benchmark. Historically, Myriad Genetics' own Equity-to-Asset has ranged from 0.48 to 0.82 over the past decade. While the company's 10-year median is 0.68 vs. the industry median of 0.59, Myriad Genetics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myriad Genetics's current Equity-to-Asset of 0.48 is 18.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current Equity-to-Asset is 0.48, which is 29% below median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (FRA:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €9.49, compared to a current price of €2.90 — trading 69.5% below its estimated fair value. The current Equity-to-Asset is 0.48, which is 29% below median its 10-year median of 0.68 and 18.6% below the Medical Diagnostics & Research industry median of 0.59. Myriad Genetics' overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Myriad Genetics (FRA:MYD), the current Equity-to-Asset is 0.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (FRA:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €2.90 is trading 69.5% below its estimated GF Value™ of €9.49.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for FRA:MYD:
Equity-to-Asset: 0.48 (29% below median its 10-year median of 0.68)
GF Value™: €9.49 vs. price of €2.90 (69.5% below fair value)
Industry Position: 18.6% below the Medical Diagnostics & Research median (#135 of 211)
No single metric tells the full story. See the FRA:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
42GF Score
Get the complete analysis for FRA:MYD
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MYD has been successfully added to your 
